ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

While the 21st century has been bumpy, it has also ushered in monumental scientific and technological breakthroughs that have ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

The birth of the world’s first gene edited babies shocked scientists and governments alike. Using CRISPR technology, a ...

Global CRISPR Technology Market OverviewThe global CRISPR technology market is poised for strong expansion, projected to grow at a robust CAGR of approximately 16% over the next five years. This ...

From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...